Binge Eating Disorder Therapeutics and Drugs Pipeline Review to 2016
WiseGuyReports.com adds“Binge Eating Disorder Therapeutics and Drugs Pipeline Review to 2016”reports to its database.
COMPLETE REPORT DETAILS @ https://www.wiseguyreports.com/reports/binge-eating-disorder-pipeline-review-h1-2016
The ‘Binge Eating Disorder - Pipeline Review, H1 2016’, provides an overview of the Binge Eating Disorder pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Binge Eating Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects.
For more information or any query mail at [email protected]
The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Binge Eating Disorder
- The report reviews pipeline therapeutics for Binge Eating Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Binge Eating Disorder therapeutics and enlists all their major and minor projects
- The report assesses Binge Eating Disorder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Binge Eating Disorder
REQUEST SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/binge-eating-disorder-pipeline-review-h1-2016
For more information or any query mail at [email protected]
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Binge Eating Disorder
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Binge Eating Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Binge Eating Disorder Overview 6
Therapeutics Development 7
Pipeline Products for Binge Eating Disorder - Overview 7
Binge Eating Disorder - Therapeutics under Development by Companies 8
Binge Eating Disorder - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Binge Eating Disorder - Products under Development by Companies 13
Binge Eating Disorder - Companies Involved in Therapeutics Development 14
Heptares Therapeutics Limited 14
Omeros Corporation 15
Opiant Pharmaceuticals, Inc. 16
Polleo Pharma Limited 17
Sunovion Pharmaceuticals Inc. 18
Teva Pharmaceutical Industries Ltd. 19
Binge Eating Disorder - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
armodafinil - Drug Profile 28
CONTINUE…..
CHECK DISCOUNT ON THIS REPORT @ https://www.wiseguyreports.com/check-discount/binge-eating-disorder-pipeline-review-h1-2016
For more information or any query mail at [email protected]
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Posted by
Vivian Dsena
on Wednesday June 08 2016, 9:47 AM EST.
All trademarks acknowledged.
Filed under Uncategorized.
Comments and Trackbacks closed.
Follow responses:
RSS 2.0
